Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Ireland
  4. Irish Stock Exchange
  5. ICON PLC
  6. News
  7. Summary
    ICLR   IE0005711209

ICON PLC

(ICLR)
Real-time Estimate Tradegate  -  05:41 2022-10-05 am EDT
196.50 EUR   +880.05%
09/26ICON plc Schedules Third Quarter 2022 Earnings Conference Call
BU
09/12Barclays Adjusts ICON's Price Target to $240 from $260, Maintains Equalweight Rating
MT
09/07UBS Initiates Coverage on ICON With Buy Rating, $270 Price Target
MT
SummaryChartsNewsRatingsCalendarCompanyFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ICON plc : ICON Announces the Commencement of Direct Trading on NASDAQ

02/05/2013 | 06:05am EDT

ICON plc, (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, commenced direct trading of ICON ordinary shares on NASDAQ (CUSIP Number G4705A 100) yesterday, 4th February 2013. This follows ICON's withdrawal from the Irish Stock Exchange on the 30th January 2013 and the termination of the ADR programme in accordance with the resolutions approved by the shareholders at the Extraordinary General Meeting of the Company on 17th December 2012.

The information contained in this release is as of 5th February 2013. The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in ICON's Annual Report for the fiscal year ended December 31, 2011 and in the forms filed with the US Securities and Exchange Commission, including the Forms 20-F, F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 82 locations in 40 countries and has approximately 9,430 employees. Further information is available at http://www.iconplc.com.

ICON/ICLR-F

ICON
Investor Relations
1-888-381-7923
or
Brendan Brennan
Chief Financial Officer
+ 353 ?1-291-2000
or
Sam Farthing
VP Investor Relations
+ 353 ?1-291-2000


© Business Wire 2013
All news about ICON PLC
09/26ICON plc Schedules Third Quarter 2022 Earnings Conference Call
BU
09/12Barclays Adjusts ICON's Price Target to $240 from $260, Maintains Equalweight Rating
MT
09/07UBS Initiates Coverage on ICON With Buy Rating, $270 Price Target
MT
09/06ICON Releases its 2021 ESG Report
BU
08/31ICON plc to Present at the 2022 Wells Fargo Healthcare Conference
BU
08/25Credit Suisse Initiates ICON at Neutral with $260 Price Target
MT
07/29ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
AQ
07/29Deutsche Bank Adjusts ICON's Price Target to $295 From $285, Maintains Buy Rating
MT
07/28Transcript : ICON Public Limited Company, Q2 2022 Earnings Call, Jul 28, 2022
CI
07/27Icon Plc : Q2 Earnings Snapshot
AQ
More news
Analyst Recommendations on ICON PLC
More recommendations
Chart ICON PLC
Duration : Period :
ICON PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Stephen A. Cutler Chief Executive Officer & Executive Director
Brendan Brennan Chief Financial Officer
Ciaran Murray Non-Executive Chairman
Tom O'Leary Chief Information Officer
Gregory P. Licholai Chief Medical & Innovation Officer
Sector and Competitors
1st jan.Capi. (M$)
ICON PLC0.00%16 082
MODERNA, INC.-50.52%49 162
LONZA GROUP AG-32.98%38 652
IQVIA HOLDINGS INC.-31.56%36 015
SEAGEN INC.-9.98%25 668
ALNYLAM PHARMACEUTICALS, INC.16.05%24 154